Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Spins Off Esperion While Retaining Former Subsidiary’s Top Compounds

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer retains undisclosed stake in Esperion, which will focus on small-molecule dyslipidemia candidate.

You may also be interested in...

Esperion Expects Phase IIb Data By Year-End On Cholesterol Candidate

The recently public company completed Phase IIa studies for lead candidate ETC-1002 and intends to complete a pair of Phase IIb studies before year-end.

Financings Of The Fortnight: Spurred By U.S. JOBS Act, Biotech IPOs Flowing Steadily Now

Plus the latest financing news from Denmark’s Symphogen, ScioDerm, Esperion Therapeutics and Intrexon.

Aiming For Non-Statin Cholesterol Drug Market, Esperion Takes $33M

Spun out from Pfizer five years ago, the Ann Arbor, Mich., company hopes its Phase II candidate can capture a share of the market for high-cholesterol drugs prescribed to statin-intolerant patients.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts